Avastin, the anti-cancer drug already widely used off-label by physicians to treat the wet form of age-related macular degeneration, is as effective as Lucentis, the gold standard for treatment of ...

Basel, March 20, 2014-Novartis has announced the launch of the Lucentis ® (ranibizumab) pre-filled syringe (PFS) in Germany, with other markets to follow throughout 2014. The Lucentis PFS, which ...

Since Lucentis is available and FDA approved, cost is surely a key factor in the NIH’s decision to compare it with Avastin. That could be a problem in the future.

But Lucentis costs as much as $2,000 per dose, so many physicians have begun substituting the similar anti-cancer drug Avastin (bevacizumab), which costs less than $150 per dose.

In DME, respondents use Lucentis in 44% and, despite lack of FDA approval for treating that condition, the specialists said they expect Eylea to erode Lucentis DME share by a third to 29%. In the US, ...

A study published in Health Affairs by researchers from the University of Michigan’s Health Management and Policy and Ophthalmology and Visual Sciences departments say research shows that Avastin and ...

A total of 759 patients were randomized into three groups to receive monthly treatment with 0.3mg Lucentis (n=250), 0.5mg Lucentis (n=252) or sham injection (control group, n=257).

Both sides in a debate over eye treatment took solace from a study that said Genentech drugs Lucentis and Avastin are equally effective in the eye but Avastin had a slightly higher rate of serious ...

FDA approves Coherus’ Cimerli™ (ranibizumab-eqrn) as the First and only interchangeable biosimilar to Lucentis ® for all five indications, with 12 months of interchangeability exclusivity ...

Analysts are expecting Eylea to peak at $1.1 billion in annual sales by 2021, provided it wins approval for other eye disorders. Lucentis brought in $1.4 billion last year and now has about 40% of ...